5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 335-338

  Advani, Pooja P ^a   Fakih, Marwan G ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

5 FU; Capecitabine; Encephalopathy; Hyperammonemia; Metastatic rectal adenocarcinoid

Indexed keywords

AMMONIA; BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

AGED; ARTICLE; BRAIN DISEASE; CASE REPORT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONTINUOUS INFUSION; DIARRHEA; DISORIENTATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERAMMONEMIA; LABORATORY TEST; LETHARGY; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; PRIORITY JOURNAL; RECTUM CARCINOMA; WEAKNESS;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BRAIN DISEASES; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; HYPERAMMONEMIA; LIVER NEOPLASMS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 79851471463     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Pirzada NA, Ali II and Dafer RM: Fluorouracil-induced neurotoxicity. Ann Pharmacology 34(1): 35-38, 2000.
2. Koenig H and Patel A: Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 23(2): 155-160, 1970.
3. Bygrave HA, Geh JI, Jani Y and Glynne-Jones R: Neurological complications of 5-fluorouracil chemotherapy: case report and review of literature. Clin Oncol 10(5): 334-336, 1998. (Pubitemid 28517414)
4. Yeh KH and Cheng AL: High-dose 5-fluorouracil infusional therapy is associated with hyperammonemia, lactic acidosis and encephalopathy. Br. J Cancer 75(3): 464-465, 1997. (Pubitemid 27051070)
5. Liaw CC, Wang HM, Wang CH, Yang TS, Chen JS, Chang HK, Lin YC, Liaw SJ and Yeh CT: Risk of hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 10(3): 275-281, 1999.
6. Mitchell RB, Wagner JE, Karp JE, Watson AJ, Brusilow SW, Przepiorka D, Storb R, Santos GW, Burke PJ and Sarai R: Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med 85(5): 662-667, 1988 (Pubitemid 19015720)
7. Espinós J, Rifón J, Pérez-Calvo J and Nieto Y: Idiopathic hyperamonemia following high-dose chemotherapy. Bone Marrow Transplant 37(9): 899, 2006.
8. Jaing TH, Lin JL, Lin YP, Yang SH, Lin JJ and Hsia SH: Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 31(12): 955-956, 2009.
9. Toyokawa A, Nakajima T, Inui K, Yamashita H, Gon H, Kanemitsu K, Tanaka K, Tsukamoto T, Hamabe Y and Ishida T: A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer. Gan To Kagaku Ryoho 36(7): 1167-1169, 2009.
10. Nakamura M, Kobashikawa K, Tamura J, Takaki R, Ohshiro M, Matayoshi R, Hirata T, Kinjyo F and Fujita J: A case of 5-fluorouracil-induced hyperammonia after chemotherapy for metastatic colon cancer. Nippon Shokakibyo Gakkai Zasshi 106(12): 1744-1750, 2009.
11. Cheung WY, Fralick RA and Cheng S: The confused cancer patient: a case of 5-fluorouracil-induced encephalopathy. Curr Oncol 15(5): 234-236, 2008.
12. Ho AY, Mijovic A, Pagliuca A and Mufti GJ: Idiopathic hyperammonaemia syndrome following allogeneic peripheral blood progenitor cell transplantation (allo-PBPCT). Bone Marrow Transplant 20(11): 1007-1008, 1997. (Pubitemid 27510969)
13. Davies SM, Szabo E, Wagner JE, Ramsay NK and Weisdorf DJ: Idiopathic hyperammonemia: a frequently lethal complication of bone marrow transplantation. Bone Marrow Transplant 17(6): 1119-1125, 1996. (Pubitemid 26235864)
14. Formica V, Leary A, Cunningham D and Chua YJ: 5-Fluorouracil can cross brain-blood barrier and cause encephalopathy: Should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma. Cancer Chemother Pharmacol 58(2): 276-8, 2006. Epub 2005 Dec 7.
15. Hook CC, Kimmel DW, Kvols LK, Scheithauer BW, Forsyth PA, Rubin J, Moertel CG and Rodriguez M: Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 31: 262-267, 1992.
16. Luppi G, Zoboli A, Barbieri F, Crisi G, Piccinini L and Silingardi V: Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. The INTACC Intergruppo Nazionale Terpia Adjuvante Colon Carcinoma. Ann Oncol 7: 412-415, 1996.
17. Fassas AB, Gattani AM and Morgello S: Cerebral demyelination with 5-fluorouracil and levamisole. Cancer Invest 12: 379-383, 1994.
18. Figueredo AT, Fawcet SE, Molloy DW, Dobranowski J and Paulseth JE: Disabling encephalopathy during 5 - fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. Cancer Invest 13(6): 608-611, 1995.
19. Nott L, Price TJ, Pittman K, Patterson K and Fletcher J: Hyperammonemia encephalopathy: An important cause of neurological deterioration following chemotherapy. Leukemia and lymphoma 48(9): 1702-1711, 2007. (Pubitemid 47386705)
20. Kikuta S, Asakage T, Nakao K, Sugasawa M and Kubota A: The aggravating factors of hyperammonemia related to 5-fluorouracil infusion - a report of two cases. Auris Nasus Larynx 35(2): 295-299, 2008.
21. Kim YA, Chung HC, Choi HJ, Rha SY, Seong JS and Jeung HC: Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol 36: 55-59, 2006. (Pubitemid 43210736)
22. Moore DH, Fowler WC and Crumpler LS: 5-Fluorouracil neurotoxicity. Gynecol Oncol 36: 152-154, 1990.